Prosecution Insights
Last updated: October 04, 2026
Application No. 18/470,859

SURFACTANT BLENDS FOR HYPOHALITE-BASED DISINFECTING COMPOSITIONS

Final Rejection §103
Filed
Sep 20, 2023
Priority
Sep 20, 2022 — provisional 63/408,225
Examiner
JAVANMARD, SAHAR
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Gojo Industries Inc.
OA Round
2 (Final)
65%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 65% of resolved cases
65%
Career Allowance Rate
487 granted / 751 resolved
+4.8% vs TC avg
Strong +34% interview lift
Without
With
+34.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 10m
Avg Prosecution
50 currently pending
Career history
786
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
46.8%
+6.8% vs TC avg
§102
14.6%
-25.4% vs TC avg
§112
16.4%
-23.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 751 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Application This Office Action is in response to Applicant's arguments filed on May 27, 2026. Claim(s) 1-22 are pending and examined herein. Response to Arguments Applicant has filed a Terminal Disclaimer over copending Application No. 18/470,622, therefore the outstanding nonstatutory obviousness-type double patenting rejection is hereby withdrawn. In view of applicant’s amendments, the 102 (a)(1) rejection of claims 1-20 as being anticipated by Encarnacion (US PG PUB 2019/0261632) of record (IDS 12/28/23, reference #72) is hereby withdrawn. Any rejection from the previous Office action not set forth on record below is hereby withdrawn. The new rejection is made in the Final Office action below as necessitated by amendment. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-22 are rejected under 35 U.S.C. 103 as being unpatentable over Miu (CA 3121871). Miu teaches sanitizing or disinfecting composition, wherein the sanitizing or disinfecting composition comprises: (a) from 0.05% to less than 0.5% by weight of a hypochlorite; (b) at least one nonionic or zwitterionic surfactant;(c) at least one anionic surfactant selected from the group consisting of:sulfates, sulfonates and any mixtures or combinations thereof;(d) wherein the composition has a pH from 8.5 to 11.8; and (e) wherein the sanitizing or disinfecting composition exhibits at least a 3-log reduction in a C. diff population within 10 minutes (claim 18). Said compositions are devoid of sodium or potassium hydroxide, as required by claims 21-22. Miu teaches Zwitterionic surfactants may be employed.Many such zwitterionic surfactants contain nitrogen. Examples of such include amine oxides, sarcosinates, taurates and betaines. Examples include C8-C18 alkyldimethyl amine oxides (e.g., octyldimethylamine oxide, lauryldimethylamine oxide (also known as lauramine oxide), and cetyldimethylamine oxide), C4-C16 dialkylmethylamine oxides (e.g. didecylmethyl-amine oxide), C8-C18 alkyl morpholine oxide (e.g. laurylmorpholine oxide), tetra-alkyl diamine dioxides (e.g. tetramethyl hexanane diamine dioxide, lauryl trimethyl propane diamine dioxide), C8-C18 alkyl betaines (e.g. decylbetaine and cetylbetaine), C8-C18 acyl sarcosinates (e.g. sodium lauroylsarcosinate), C8-C18 acyl C1-C6 alkyl taurates (e.g. sodium cocoylmethyltaurate), C8-C 1 8 alkyl iminodiprop ionates (e.g. sodium lauryliminodipropionate), and combinations thereof. Lauryl dimethyl amine oxide (Ammonyx LO) myristyl dimethyl amine oxide (Ammonyx MO), decylamine oxide (Ammonyx DO) are examples of suitable zwitterionic surfactants, available from Stepan Co. [0060]. Miu teaches an anionic surfactant may be included as surfactant aid. An example of such a suitable surfactant aid is an aromatic sulfonate, such as sodium xylene sulfonate ("SXS") or sodium lauryl sulfate (SLS) [0066]. Miu teaches pH values for the present compositions may be about 7 to 12.5 [0084]. Miu teaches surfactant concentrations may typically be far lower than many other bleach formulations, e.g., given the low level of other active ingredients in the formulation. For example, total surfactant concentration may range from 0.001% by weight to 1% by weight, from 0.01% to 0.5% by weight, from 0.01% by weight to 0.1% by weight. The ratio of surfactant to hypohalite or other free available halide oxidant may be from 1:1 to 100:1, from 3:1 to 50:1, from 5:1 to 20:1 or from 5:1 to 15:1 [0071]. Examiner notes that the limitations regarding surface tension are considered properties inherent in the disclosed active agent. "Products of identical chemical composition cannot have mutual exclusive properties." Any properties exhibited by or benefits from are not given any patentable weight over the prior art provided the composition is inherent. A chemical composition and its properties are inseparable. Therefore, if the prior art teaches the identical chemical structure, the disclosed properties are necessarily present. In re Spada, 911 F.2d 705,709, 15 USPQ 1655, 1658 (Fed. Cir. 1990). See MPEP 2112.01. The burden is shifted to the applicant to show that the prior art product does not inherently possess the same properties as the instantly claimed product. Miu does not specifically exemplify a composition wherein the first surfactant and second surfactant have at least a 2-carbon unit difference in length as required by the instant claims. More specifically, it is not exemplified wherein the first surfactant is sodium lauryl sulfate or sodium myristyl sulfate and the second surfactant is myristamine oxide or cocobetaine, as required by claims 10, 11, 16, and 17. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have known of the disinfecting compositions as taught by Miu to arrive at the instant invention. Miu teaches a variety of anionic and zwitterionic surfactants that are embraced by the instant invention. The specific combination of features claimed is disclosed within the broad generic ranges taught by the reference but such "picking and choosing" within several variables does not necessarily give rise to anticipation. Corninq Glass Works v. Sumitomo Elec., 868 F.2d 1251, 1262 (Fed. Circ. 1989). Where, as here, the reference does not provide any motivation to select this specific combination of variables, anticipation cannot be found. That being said, however, it must be remembered that "[w]hen a patent simply arranges old elements with each performing the same function it had been known to perform and yields no more than one would expect from such an arrangement, the combination is obvious". KSR v. Teleflex, 127 S, Ct. 1727, 1740 (2007)(quoting Sakraida v. A.G. Pro, 425 U.S. 273, 282 (1976). "[W]hen the question is whether a patent claiming the combination of elements of prior art is obvious", the relevant question is "whether the improvement is more than the predictable use of prior art elements according to their established functions." (Ida). Addressing the issue of obviousness, the Supreme Court noted that the analysis under 35 USC 103 "need not seek out precise teachings directed to the specific subject matter of the challenged claim, for a court can take account of the inferences and creative steps that a person of ordinary skill in the art would employ." KSR v. Teleflex, 127 S, Ct. 1727, 1741 (2007). The Court emphasized that "[a] person of ordinary skill is... a person of ordinary creativity, not an automaton." Id. at 1742. Consistent with this reasoning, it would have obvious to have selected various combinations of various disclosed ingredients from within a prior art disclosure, to arrive compositions "yielding no more than one would expect from such an arrangement". Additionally, varying the concentration of the surfactants of the composition would be obvious to one of ordinary skill in the art, absent secondary considerations (i.e., unexpected results). Generally, mere optimization of ranges will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. "When the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimal or workable ranges by routine experimentation. In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955); see also In re Peterson, 315 F. 3d at 1330, 65 USPQ 2d at 1382 "The normal desire of scientists or artisans to improve upon what is already generally known provides the motivation to determine where in a disclosed set of percentage ranges is the optimum combination of percentages." MPEP 2114.04. Thus, based on the foregoing reasons, the instant claims are deemed unpatentable over the cited reference. Conclusion Claims 1-22 are not allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sahar Javanmard whose telephone number is (571)270-3280. The examiner can normally be reached on Monday-Friday, 9:00-5:00 EST. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James Alstrum-Acevedo can be reached on 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. /SAHAR JAVANMARD/Primary Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

Sep 20, 2023
Application Filed
Jan 09, 2026
Non-Final Rejection (signed) — §103
Feb 27, 2026
Non-Final Rejection mailed — §103
May 27, 2026
Response Filed
Sep 09, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12746252
INTERFERON GENE STIMULATOR COMPOSITION COMPRISING INDOLIZINE DERIVATIVE AS ACTIVE INGREDIENT
3y 5m to grant Granted Sep 29, 2026
Patent 12741967
CONDENSED HETEROCYCLIC COMPOUND HAVING A SULFONAMIDE GROUP OR SALT THEREOF, AGRICULTURAL OR HORTICULTURAL INSECTICIDE OR ANIMAL ECTOPARASITE OR ENDOPARASITE CONTROL AGENT COMPRISING THE COMPOUND OR THE SALT THEREOF, AND METHOD FOR USING THE COMPOUND OR THE SALT THEREOF, THE INSECTICIDE, OR THE CONTROL AGENT
3y 0m to grant Granted Sep 22, 2026
Patent 12723044
HETEROCYCLIC SUBSTITUTED FUSED y-CARBOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF AND USE THEREOF
3y 5m to grant Granted Sep 01, 2026
Patent 12715846
CRYSTAL FORM OF QUINOLINONE COMPOUND AND USE THEREOF
4y 2m to grant Granted Aug 25, 2026
Patent 12715847
ANTIBACTERIAL COMPOUNDS
3y 0m to grant Granted Aug 25, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
65%
Grant Probability
99%
With Interview (+34.1%)
2y 10m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 751 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month